Overview

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Status:
RECRUITING
Trial end date:
2026-12-24
Target enrollment:
Participant gender:
Summary
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Phase:
PHASE2
Details
Lead Sponsor:
Nanjing Leads Biolabs Co.,Ltd
Collaborator:
Sun Yat-sen University
Treatments:
Bevacizumab
Carboplatin
Docetaxel
Injections
Paclitaxel
Pemetrexed